Skip to contentpdufa.bio

Revita (Revita DMR System)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

Revita (Revita DMR System) is a Fractyl Health, Inc. program in post-GLP-1 weight maintenance. Its next catalyst is a Readout in Q1 2027.

GUTS catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: post-GLP-1 weight maintenance. Sponsor: Fractyl Health, Inc. (GUTS). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q1 2027GUTS

Questions

When is Revita (Revita DMR System)'s next FDA decision or readout?

The next tracked catalyst for Revita (Revita DMR System) is a Readout in Q1 2027.

What happened at Revita (Revita DMR System)'s most recent FDA decision?

No FDA decision for Revita (Revita DMR System) is in our archive yet.

What is Revita (Revita DMR System) used for?

In our records Revita (Revita DMR System) is under review or in development for post-GLP-1 weight maintenance.

Who makes Revita (Revita DMR System)?

Fractyl Health, Inc. (GUTS).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.